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C±H Functionalization for 
Hydrogen Isotope Exchange  
Jens Atzrodt,[a], Volker Derdau,[a], William J. 





Abstract: The varied applications of hydrogen isotopes 
(deuterium, D, and tritium, T) in the physical and life sciences 
demands a range of methods for their installation in an array of 
molecular architectures. In this review, we describe recent 
advances in synthetic C±H functionalization for hydrogen 
isotope exchange. 
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The catalytic activation of C±H bonds has been in the 
spotlight of research for several decades.[1,2] In addition to the 
numerous investigations on C±H functionalization towards C±
C,[3] C±X,[4] C±N,[5] or C±O[6] bond formation, hydrogen isotope 
exchange (HIE)[ 7, 8] for selective installation of C±D[9] and C±T[10] 
bonds is also of appreciable practical importance. Generally, the 
overall process can be understood as catalytic replacement of a 
C±H bond (mainly by transition metals) followed by a 
substitution either by carbon, halogen, oxygen or nitrogen atoms, 
or hydrogen isotopes (HIE) (see Scheme 1). Therefore, the HIE 
reaction can be considered as the most fundamental of all C±H 
functionalization processes.   
 
Scheme 1. A principle method of C-H functionalization to form C-D/T or C-X 
(C, N, O) bonds. 
Incorporation of deuterium or tritium into an organic molecule 
can be achieved by two principle routes, either by a conventional 
multistep synthesis or by direct HIE. Depending on the 
complexity of the chemistry, the chemical structure of the target 
molecule, and the labeling position, a classical synthesis 
approach, starting from appropriate commercially available 
labeled precursors, can be very time and resource consuming. 
Alternatively, the HIE reaction enables a direct deuterium or 
tritium labeling of the desired target molecule and, thus, may 
circumvent the need for additional synthetic steps (e.g. 
precursor synthesis or multi-step routes from isotopically-labeled 
building blocks). If carried out directly on the target molecule, or 
an advanced intermediate thereof, the HIE labeling approach 
bears appreciable potential for time and cost savings and, thus, 
has become a desireable strategy for the delivery of deuterium 
or tritium into organic molecules.[11]  
However, after a period of intensive research in the 1960s 
and 1970s, it took until the mid-1990s before the HIE approach 
experienced another resurgence; accordingly, our 2007 review 
was entitled ³The Renaissance of H/D Exchange´[7] Since then, 
the need for stable isotopically labeled compounds (and, to a 
lesser extent, their radiolabeled analogues) has further 
escalated. This is largely due to the rapid development of high 
performance mass spectrometry and the enhanced application 
of liquid chromatography-mass spectrometry (LC-MS)-based 
analysis. The ability for precise measurement of isotope ratios 
promotes a dynamic view on biosynthetic pathways, protein 
turnover, and systems-wide metabolic networks and, thus, has 
paved the way for a number of scientific breakthroughs in 
biomedical research.[ 12 ] Additionally, in medicinal chemistry, 
replacement of hydrogen by deuterium has recently received 
much attention as a way to alter ADME properties of existing 
drug candidates.[ 13 ] Associated with all of this, C±H 
functionalization continues to be a hot topic for late stage 
elaboration of complex molecules.[2a]  
In relation to the synthesis of labeled compounds, the last 
decade has seen a shift in research focus from hetero- to 
homogeneous catalytic HIE method development. Having stated 
this, both classes of labeling approach have complementary 
applications and are both used regularly. Typically, 
heterogeneous metal-catalyzed HIE results in relatively 
unspecific incorporation of numerous deuterium atoms into a 
molecular substrate (Scheme 2, centre). Accordingly, 
heterogeneous metal-catalyzed H/D exchange tends to be the 
method of choice for preparation of stable isotopically labeled 
internal standards (SILS) for LC-MS/MS investigations. For SILS 
applications, the overlap of the mass signals for the unlabeled 
analyte relative to the signals for the internal standard should be 
as low as reasonably feasible. As a consequence, 
heterogeneous exchange methods have been optimized to 
incorporate 3 ± 5 deuterium atoms in the case of small 
molecules without chlorine, bromine, or sulfur-containing 
functionalities and where the remaining amount of unlabeled 
(D0) is negligible.[14] In contrast, homogeneous metal catalyzed 
HIE methods are typically much more selective, incorporating 
deuterium only at specific positions in the molecule (e.g. next to 
a directing group; Scheme 2, right). Therefore, these methods 
are of particular importance for tritium incorporation via H/T 
exchange.[10,11]  
Acid/base-mediated labeling methods are still used. The 
selectivity of these methods largely depends on innate electronic 
activation within the target molecule (e.g. for electrophilic 
aromatic substitution; Scheme 2, left). 
 
Scheme 2. Illustration of various selectivities available by distinct HIE methods. 
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In this review, we describe current progress and remaining 
challenges in synthetic HIE methods published since 2007. The 
review complements our sister review, ³Applications of 
Hydrogen Isotopes in the Life Sciences´ which details the 
expansive application areas for deuterium and tritium isotopes in 
both the physical and life sciences.[15]   
2. Acid/Base-mediated Labeling 
Even though pH-dependent H/D-exchange reactions are 
amongst the oldest methods used to mediate such labeling, 
there are still new applications and examples being reported. 
While simple Brönsted acids such as DCl[16]  or D2SO4[17] are 
mostly used to introduce deuterium into activated aromatic 
compounds, bases like NaOD/D2O,[ 18 ] DMAP/D2O,[ 19 ] 
Na2CO3/D2O[20] or even near-supercritical D2O[21] are convenient 
reagents with which to introduce the hydrogen isotope into 
aliphatic CH-positions. Due to the fact that the isotope source is 
used in high excess there are only a few acid/base-catalyzed 
protocols known to introduce tritium.[11] Most of these examples 
are of older provenance, with no new application having been 
reported in the last ten years, most probably due to the 
development of more effective alternative tritiation methods. 
2.1 Acid-mediated labeling 
As peptides have become increasingly important in 
pharmaceutical research, there has also been a significant 
increase of reported methods to prepare deuterium-labeled 
amino acids or peptides. For example, Hashimoto et al. reported 
the deuteration of D-amino acids derivatives by triflic acid 
(trifluoromethanesulfonic acid) with high deuterium content (1ĺ2 
and 3ĺ4; Scheme 3).[22] In one example, a pentapeptide was  
deuterated at room temperature in 9 hours with up to 8 
deuterium atoms introduced at the aromatic positions.[23] 
 
Scheme 3. Acid-mediated labeling of amino acid derivatives.  
 
Martins and Lautens have also devised a quick and effective 
method for deutering anilines under microwave conditions.[16d] 
DCl was generated in situ from D2O and HCl, mediating H/D 
exchange via electrophilic aromatic substitution (5ĺ6; Scheme 
4). 
 
Scheme 4. Microwave-assisted deuteration of anilines under acidic conditions.  
The arenium acid, 7 >PHVLW\OHQHí+@+ was demonstrated to 
be an extraordinarily active H/D exchange catalyst for the 
perdeuteration of polycyclic aromatic hydrocarbons (8ĺ9; 
Scheme 5). Using ambient temperatures and C6D6 as the 
deuterium source, high isolated yields and excellent degrees of 
deuterium incorporation were achieved with the substrates p-
terphenyl, fluoranthene, pyrene, triphenylene, and corannulene. 
More generally, the concept of pairing a cationic proton donor 
with a weakly coordinating anion has enabled the development 
of strong Brønsted acids that lack the nucleophilic and oxidative 
properties of traditionally used reagents such as H3PO4 or 
H2SO4.[24]  
 
Scheme 5. Arenium acid-catalyzed deuteration of extended aromatic systems. 
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Another recently reported pathway to access D-deuterated 
amino acids (13) is via enantioselective transfer deuteration of 
ketimines (10) with chiral phosphoric acid (12) and by use of 
benzothiazoline (11) as deuterium donor (10+11+12ĺ13; 
Scheme 6).[25] 
 
Scheme 6. Phosphoric acid-catalyzed asymmetric reductive deuteration of 
imines. D-incorporation is assumed to be quantitative. 
In summary, acid-mediated HIE is most powerful (and 
practicable) when harnessing the innate reactivity of 
electronically-activated aromatics and unsaturated molecules. It 
is most useful for structurally simple molecules, where the 
chance of degrading complex functionalities within the molecule 
is minimal. Indeed, the cost-efficiency of such labeling methods 
continues to make acid-mediated labeling an attractive option. 
As in Scheme 6, and beyond using acids solely as part of the 
isotope source, further developments where acids are used a 
supramolecular director of reactivity have the potential to expand 
the toolbox for enantioselective labeling. 
2.2 Lewis acids & frustrated Lewis pairs 
The H/D exchange of arenes in acidic media by transition-
metal and main-group-metal complexes, as well as common 
inorganic salts has been studied intensively by Goddard and 
Gunnoe et al. (14ĺ15; Scheme 7).[ 26 ] As part of this, the 
influence of Lewis acidity, anions, charge, and ligands have 
been evaluated, leading to the conclusion that the determination 
of H/D exchange activity in acidic media was not related to the 
formatLRQRIPHWDOíFDUERQERQGVLH not &í+ functionalization 
via an oxidative addition mechanism). The experimental data 
(regioselectivity, activation energy, kinetics, and isotope and 
solvent effects) and density functional theory (DFT) calculations 
supported a proton catalysis mechanism and, consequently, 
highly Lewis acidic metal compounds, such as aluminum(III) 
triflate, were extraordinarily active in the H/D exchange reactions.  
 
Scheme 7. Lewis acid-assisted labeling in acidic media. 
Kemnitz and Braun et al. described a new catalytic method 
for efficient H/D exchange reactions at aromatic and aliphatic C±
H/C±D bonds (16ĺ17 and 18ĺ19; Scheme 8).[ 27 ] Solid 
nanoscopic Lewis acids, like aluminium chlorofluoride, and high-
surface aluminium trifluoride (HS-AlF3) were used as catalysts to 
deliver deuterated benzene and alkanes at mild to moderate 
temperatures (40 °C to 110 °C). 
 
Scheme 8. Aliphatic H/D exchange using high surface-AlF3.  
A further area gaining increased attention in the context of 
hydrogen isotope exchange reactions is the application of 
Frustrated Lewis acid/base pairs (FLPs).[28] There are already 
some examples demonstrating that H/D exchange in the gas 
phase takes place.[29 ] In another example, a series of Lewis 
base/borane mixtures were used in the reduction of imines,[30] or 
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carbonyl groups (for example, 20ĺ21; Scheme 9).[ 31 ] An 
equivalent H/D or H/T exchange reaction on hydrocarbons has 
yet to be realised.  
 
Scheme 9. Frustrated Lewis pairs in HIE. 
 As with the section 2.1, the methods described in section 
2.2 are most appropriate for structurally simple molecules, or 
molecules in which there is a targeted, reducible functionality.  
Using Lewis acids in combination with isotopic media, future 
challenges lie in understanding how such methods can catalyze 
or mediate labeling at lower temperatures.  
  
2.3 Base-mediated labeling 
A convenient way to synthesize deuterium labeled amines 
and nitrogen-containing heterocycles was reported by Zhang 
and Yan et al. (22ĺ23; Scheme 10).[32] Utilizing a base and 
DMSO-d6, a free radical deuteration mechanism has been 
postulated, starting by deprotonation of DMSO. Best deuteration 
results were achieved with NaH and KOtBu. 
In another approach to deuterate amino acids, L-alanine was 
catalytically transformed into deuterated D-alanine by reaction 
with an aldehyde 24 and a chiral base 25 in 67%ee, without any 
use of protecting groups (Scheme 11).[33] When L-alanine was 
reacted for 3 days instead of 4 h, the D/L ratio of deuterated 
alanine changed to 1:1. The drop in the D/L ratio (5:1 to 1:1) was 
considered to be due to catalytic racemization of deuterated D-
alanine. This system could also be used for catalytic deuteration 
of D-alanine with retention of stereochemistry to give deuterated 
D-alanine. 
In conjunction with labeling phenols, Xie and Chen et al. 
developed a highly effective method using NaOH as a catalyst 
and D2O as the deuterium source under microwave irradiation at 
180 °C (26ĺ27; Scheme 12).[ 34 ] High degrees of both 
regioselectivity and deuterium incorporation for the ortho- and/or 
 
Scheme  10. Base-mediated labeling of benzylamines. 
 
Scheme 11. Enantioselective deuteration of amino-acids. 
para-hydrogens relative to the oxygen atom were achieved. The 
method showed a relatively high functional group tolerance and 
allowed the deuteration of complex pharmaceutically interesting 
substrates, such as Desvenlafaxine (Scheme 12). 
Finally, it can be summarized that the field of acid/base-
catalyzed H/D exchange is slowly progressing with some very 
convenient new approaches and methods emerging. 





Scheme 12. Base-medated HIE with Phenols.  
3. Heterogeneous Catalysis 
In homogeneous catalysis, selectivity is one of the major 
objectives, while in heterogeneous catalysis, the high catalyst 
reactivity, which can be fine-tuned by activation of the catalyst 
surface, is a more prominent advantage. The reasons for 
needing different types of labeling selectivity depend on the end 
application of the labeled molecule, and this is discussed in full 
LQ RXU VLVWHU UHYLHZ ³Applications of Hydrogen Isotopes in the 
Life Sciences´[15] Generally, heterogeneous catalysis is applied 
if several deuterium/tritium atoms are required to be introduced. 
Therefore, this method is mainly applied to prepare deuterated 
MS standards for LC-MS/MS analysis. Another technical 
advantage of heterogeneous catalysis is the possibility to 
remove the catalyst by simple filtration on reaction completion. 
Moreover, in exchange processes that occur without side 
reactions or decomposition, no further purification step is 
necessary. However, due to the generally low levels of 
selectivity there is always the possibility of unwanted 
dehalogenation, hydrogenation, hydrolysis, or, under more harsh 
conditions, epimerization and racemization. Additionally and in 
spite of the methodological improvements in recent years, 
adjustment and optimization of the reaction conditions for each 
substrate are usually unavoidable.  
High activity for H/D exchange by heterogeneous 
approaches has been found with palladium, platinum, rhodium, 
nickel, cobalt, and, more recently, ruthenium catalysts. On the 
other hand, no particular exchange activity has been observed in 
heterogeneous reaction procedures with either iridium or iron, 
which are used with success in homogeneous catalysis (see 
next section). Regarding the isotope source, gaseous deuterium 
or tritium, deuterium- or tritium-oxide, and deuterated protic 
solvents that transfer their labile deuterium to the substrate have 
all been used as isotopic hydrogen sources.[7, 8] The most recent 
method developments and trends of heterogeneously catalyzed 
HIE reactions are now described, below.  
3.1 Transition metal-catalyzed HIE reactions 
Palladium is amongst the most common transition metals 
applied in C±H functionalization, and there are many recent 
applications of such heterogeneously catalyzed HIE reactions 
reported.[8e, 35, 36, 37, 38 , 39, 40, 41 ] In principle, Pd/C is one of the 
most widely used heterogeneous catalysts in organic synthesis, 
as typically applied in hydrogenation reactions. Many different 
catalyst variations are commercial available, generating a 
complex portfolio of hydrogenation reactivity measured in turn-
over-number (TON) and turnover-frequency (TOF) of different 
model reactions. Pd/C has also proven its usefulness in HIE 
reactions. However, detailed descriptions of the catalyst 
(supplier, batch, etc.) are essential to fully reproduce published 
results.  
In relation to isotope incorporation, a comprehensive 
investigation of the scope of the Pd/C±H2-D2O has been 
accomplished over the last ten years. More specifically, aliphatic 
secondary alcohols and ketones have been deuterated with high 
deuterium contents of >90% in redox processes; interestingly, 
the ketones reached higher levels of deuterium incorporation 
compared to the alcohols.[35]  Furthermore, kinetic investigation 
of Pd-catalyzed D2O and H2 reactions have been performed, 
TON for such processes were calculated, and investigations 
performed for hydride catalyst activation.[36, 37, 38]  
Pd/C has also been applied to introduce tritium into 
molecules (for applications, see our sister review).[15] In a recent 
example, the HIE reaction of sodium 4-phenylbenzoate in a 
diluted tritium atmosphere was accomplished generating the 
labeled product with a low specific activity of 0.8 ± 0.2 
Ci/mmol)[39, 40]  (29.2 Ci/mmol[11]  = 100% tritium at a C±H 
position). However, heterogeneous catalyzed H/T-exchange 
reactions remain a relatively neglected field of research.     
Another approach to influence the activity of the 
heterogeneous catalyst is to adjust the Pd/C activity by 
modification of the catalyst surface in combination with organic 
bases. This has been extensively studied in hydrogenation 
reactions of CBz- or benzyl-protected ethers or amines.[42]  In a 
HIE reaction with the catalyst Pd/C±ethylenediamine complex 
[Pd/C(en)], for example, only deuterium exchange at the 
benzylic positions took place. The benzylic site of 1-benzyloxy-3-
phenylpropane was deuterated at 50 °C using 5% Pd/C(en) 
without the hydrogenolysis of the benzyl ether (yield 90%), while 
the use of Pd/C alone caused a significant deprotection of the O-
benzyl group to afford the benzyl ether in only 36%.[43]  Finally, it 
should be noted that other organic support materials have been 
applied in successful deuterations, e.g. Pd/BN (BN=boron 
nitride)[ 44 ] or Pd/PVP (PVP = poly(N-vinyl-2-pyrrolidone), 
demonstrating a broad acceptance of different carrier 
materials.[45]  
Besides organic catalyst support, the effect of inorganic 
catalyst carriers in HIE reactions has also been studied 
intensively. One major field is the high-temperature solid-state 
catalytic isotope exchange (HSCIE) method developed by 
Myasoedov et al., which is based on the action of gaseous 
deuterium/tritium on a solid, highly dispersed mixture of the 
substrate and the transition-metal catalyst (mostly applying an 
inorganic carrier e.g. CaCO3, BaSO4, etc.) without any solvent at 
high temperatures (130-180 °C).[46, 47, 48] This isotope exchange 
method proved to be highly efficient in the selective, 
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racemization-free deuteration/tritiation of amino acids and 
peptides.  
 
Scheme 13. Recent applications of heterogeneous Pd- or Rh-catalyzed HIE 
for tritiation. Labeling position not specified.  
Some recent examples have further broadened the scope of 
this method in recent years (Scheme 13). For example, the 
effect of catalyst and temperature on the HSCIE reaction of 
isopentenyladenine 28 was studied; this substrate was required 
for investigation of the specific binding with the AHK4 cytokinin 
receptor. Applying the standard procedure at 160 °C and Pd on 
BaSO4 or CaCO3 for 20 minutes afforded tritiated 
isopentenyladenine in moderate yields.[47] If non-diluted tritium 
gas was applied, higher specific activities were reached as 
reported in the HSCIE reaction of methylurea 29. After reaction 
of 29 with PdO/BaSO4 at 150 °C for 15 min under a tritium 
atmosphere, the tritiated analogue was isolated in 30-35% yield 
and with high specific activity.[48] In another example, SB258585 
30 was tritium labeled without loss of the iodine moiety. This 
outcome is considered to be quite remarkable as these reaction 
conditions are the standard procedures for iodine/tritium 
exchange in solution. SB258585 30 is an antagonist of the 5-HT-
6 receptor and exhibits antidepressant, nootropic, and anxiolytic 
properties. The compound is considered to be a promising 
structure for the treatment of schizophrenia, cognitive disorders, 
or Alzheimer¶V disease.[ 49 ] Most interestingly, the Myasoedov 
method has been successfully applied to label larger peptides, 
like insulins. Recombinant insulin 31 was subjected to HSCIE 
reaction (5% Pd/BaSO4, 30 kPa T2/H2, 20 min, 120 °C) with a 
hydrogen±tritium 1:1 mixture to produce the 3H-insulin with a 
specific activity of 40 Ci/mmol and an overall radioactivity 
amount of 3 mCi being isolated (Scheme 14).  After digestion 
and MS analysis, the percentage of 3H-labeling for each amino 
acid was determined. Histidine (46%), arginine (13%), and 
glycine (5%) were identified as the amino acids with the highest 
tritium content. However, around 36% of the total radioactivity 
was distributed unselectively within the other amino acids.[50] 
Zolotarev et al. examined the HSCIE reaction under the 
action of spillover hydrogen[51] on amino acids or peptides as 
applied on alumina oxide. Activation energies for hydrogen 
isotope exchange with tritium and deuterium in glycine and Į-
aminoisobutyric acidwere measured experimentally and 
calculated using a quantum chemical approach. The activation 
 
Scheme 14. Pd-catalyzed tritium labeling of insulin.  
energies for H/T and H/D exchange in all measured amino acids 
were very close, with the hydrogen isotopes reacting at virtually 
the same rate. It was shown that for the solid-state reaction 
studied, with deuterium and tritium the kinetic isotopic effect was 
í, which is several times smaller than the kinetic isotopic 
effect in hydrogen transfer reactions in the liquid phase. Using 
the HSCIE reaction, it becomes possible to substitute hydrogen 
for deuterium or tritium almost quantitatively in a series of amino 
acids without racemization.[ 52 ] This method has also been 
applied in the tritiation of GABA and L-DOPA,[53] brassinolide,[54] 
ataluren (PTC124),[ 55 ] druglike glutamate and dopamine 
ligands,[56] maraviroc, a new generation agent for HIV treatment 
blocking chemokine receptors CCR-5,[57] D-ribose,[58] serotonin 
(5-methoxytryptamine), and diazepam (see, for example, 32-36, 
Scheme 15).[59]     
 
Scheme 15. Applications of high temperature solid-state catalytic isotope 
exchange (HSCIE).  
In addition to palladium, platinum also plays an appreciable 
role in heterogeneous catalyzed HIE reactions. Platinum has 
especially proven to be very efficient for aromatic C±H positions, 
with much higher deuterium incorporation compared to aliphatic 
C±H positions. For example, Sajiki et al. reported an effective 
deuteration method for aromatic rings using the Pt/C±D2O±H2 
system. They demonstrated the complete labeling of phenol at 
room temperature; additionally, other electron-rich aromatic 
nuclei were efficiently deuterated under mild conditions.[ 60 ] 
However, the use of hydrogen gas for catalyst activation can be 
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avoided within this general Pt-catalyzed approach. Recently, a 
method for deuteration of several arenes under Pt/C-iPrOH-D2O 
conditions was reported (37ĺ38; Scheme 16). Remarkably, the 
activation of the metal surface was performed by in situ 
generated hydrogen/deuterium through transfer hydrogenation 
from iso-propanol. This developed external hydrogen gas-free 
method could, therefore, be used on process scale or for 
substrates where undesired Pt-H2-reductions were otherwise 
likely.[61] 
   
Scheme 16. Global deuteration using Pt/C. 
There have also been several cases where the design and 
structure of the heterogeneous catalysts has been studied and 
ways in which to optimize reactivity and efficiency in the 
hydrogenation or HIE reaction have been found. In one example 
Nakamura et al. have demonstrated high durability in ten 
catalytic cycles of a simple HIE reaction with hydrogen and 
deuterium using a nitrogen-doped graphite surface. The applied 
ion bombardment enhanced extensively the durability of 
deposited Pt clusters for H2íD2 exchange reactions.[62]  
The difficulty in finding a suitable method for the deuteration 
of unactivated hydrocarbons was addressed in 2008 by applying 
Rh/C±H2-D2O as catalytic system. At 160 °C linear alkanes were 
deuterated with grades higher than 90% deuterium at each 
carbon atom. In the case of n-octacosane (C28H58), full 
deuteration with up to 58 exchanged deuterium atoms was 
determined. The method was also successfully applied to a 
number of cyclic hydrocarbons, such as D-cholestane or 
cyclopentadecane, with moderate to high deuterium 
incorporation.[63, 64] 
One of the major improvements in this general field over the 
past 10 years has been the application of ruthenium in 
heterogeneous catalyzed HIE reactions. While ruthenium 
catalysts have been used in selective homogeneous HIE 
reactions for many years, heterogeneous ruthenium catalysts on 
support have been appreciably neglected. In a first example, a 
regioselective deuteration of carbinol carbons was achieved by 
the combination of ruthenium on carbon (Ru/C), hydrogen gas, 
and deuterium oxide (D2O). The reaction proceeded with high 
deuterium efficiency and regioselectivity at the position D to the 
hydroxy unit, with hydrogen exchange of either one deuterium 
atom for secondary or two deuterium atoms for primary alcohols, 
respectively (39ĺ40; Scheme 17). Testing 2-(S)-hydroxynonane 
(97%ee) under the reaction conditions with H2 rather than D2, it 
was found that the D-hydroxy position was completely racemized 
(1.8%ee). This method is applicable to the deuteration of various 
aliphatic alcohols, including diol and triol derivatives.[65] 
 
Scheme 17. Heterogeneous Ru-FDWDO\]HGĮ-deuteration of alcohols.   
The same general method was further explored in the 
deuteration of various sugars. Several pyranosides, such as 1-
deoxy-D-glucopyranoside, E-D-galactopyranoside, D-(+)-
trehalose,E-D-ribofuranoside, and D-(+)-saccharose were 
successfully deuterated with up to 100% deuterium at the 2-, 3-, 
4-, and 6-position without any loss of stereoinformation.[66] By 
using protected sugars, a site-selective deuteration allowed the 
synthesis of the various deuterated sugars in a regio- and 
stereoselective fashion. Nearly quantitative deuterated sugars 
could be obtained following simple work-up processes, such as 
filtration of the heterogeneous Ru/C catalyst and extraction 
(41ĺ42; Scheme 18).[67] It was proposed that the ring strain that 
would be induced by oxidising (dehydrogenating) the hydroxyl 
groups to the corresponding carbonyl group en route to 
epimerisation allows for kinetically competitive and stereo-
retentive oxidative addition into the C-H bonds. Thus, unlike the 
acyclic example discussed above (Scheme 17), no 
epimerisation occurs during C±H cleavage in labeling the cyclic 
sugars.  
 
Scheme 18. Ru-catalyzed deuteration of sugar derivatives.  
Cobalt and iron were also examined in an HIE reaction of D5-
1-pentene under standard Fischer-Tropsch conditions. A 
significant inhibition of the catalyst in the presence of carbon 
monoxide was observed.[68, 69] In material science, the study of 
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HIE in understanding hydrogen storage and dissociation 
processes is of fundamental importance. In one example, HIE 
was studied in polycrystalline tungsten at 320 and 450 K. It was 
concluded that hydrogen does not freely diffuse through 
hydrogen saturated layers. The transport of hydrogen is a chain 
of trapping, de-trapping, and diffusion events.[70] Furthermore, 
the results reported by Rai et al. indicate that graphite (carbon 
surface) also may have a significant influence on HIE 
processes.[ 71 ] Assiociated with all of this and into the future, 
understanding of the physical processes in heterogeneous 
catalysis is expected to improve the HIE applications in general.  
 
3.2 HIE reactions with catalyst mixtures 
Where individual heterogeneous catalyst systems have 
found applications in HIE in their own right, more recent 
advances have been made using combinations of catalysts to 
produce labeling strategies complementary to those of either 
catalyst on its own. The fundamental reasons for these observed 
effects remain an unknown in this area of applied synthesis. 
In 2006, Sajiki et al. made the first report of a synergistic 
effect when using catalyst mixtures of Pd/C and Pt/C for H/D 
exchange reactions (Pd-Pt-D2O-H2).[72] Since then this principle 
has been demonstrated successfully on several occasions. In a 
specific example, Pd/C and Pt/C catalyst mixtures revealed an 
almost quantitative deuteration of a number of bisanilines. With 
this method, benzylic and aromatic positions were deuterated 
very effectively (43 ± 45; Scheme 19).[73]  
 
Scheme 19. Synergic Pd/Pt-catalyzed HIE with bisanilines.  
In another example reported by Derdau and Atzrodt, the 
synergistic effect was proven after NaBD4-activation of the 
catalyst mixture resulting in significantly higher deuterium 
incorporations compared to those obtained with the single 
catalysts induced H/D exchange of heterocycles (see Scheme 
20).[74]   More specifically, a significant synergistic effect could 
be observed for quinoline-2-carboxylic acid 46, 
aminonaphthalene 47, and 5-aminobenzothiophene 48. For 8-
methylquinoline 49, an almost complete deuteration was 
achieved with the Pd/Pt/C catalyst mixture and, in contrast to 
Pd/C alone, a representative mass peak at M+9 could also be 
identified and, thus, the material could be used as precursor for 
internal MS standard preparation.  
In the same year, similar results were reported by Sajiki et al. 
with bimetallic Pt/Pd/C catalysts produced by various reducing 
agents. [75] Depending on the reducing agent, the activity of the 
in situ prepared active bimetallic catalysts differed. Interestingly, 
the NaBH4 reduced catalyst showed the highest overall catalytic 
activity for the deuteration of 1,2,4,5-tetramethylbenzene and 
was even superior than the species reduced by H2 alone 
(50ĺ51, Scheme 21). Recently the mixed catalyst 10% Pd/C 
(10 wt %) and 10% Pt/C (25 wt %) was utilized for deuteration of 
Mesalamine at 145 °C, using D2O as the deuterium source 
under a hydrogen atmosphere.[76] 
 
Scheme 20. Synergistic effect in the NaBD4 activated microwave-induced H/D 
exchange.  
 




In order to establish a suitable approach for the large scale 
synthesis (1-12 g scale) of deuterated arylamines which 
demonstrate a great potential for use in optoelectronic devices, 
the deuteration of diphenylamine, N-phenylnaphthylamine, N-
phenyl-o-phenylenediamine, and 1-naphthylamine (via H/D 
exchange in D2O at 80 °C, catalyzed by Pt/C and Pd/C) was 
examined. While primary and secondary aromatic amines 
showed high overall deuteration incorporation (88-96%), tertiary 
amines failed completely.[77]    
Mixtures of heterogeneous Pt/C and Rh/C have been 
applied in deuteration of alkanes in a mixture of i-PrOD-d8 and 
D2O.[ 78 ] The reported multi-deuteration was initiated by the 
transition metal-catalyzed dedeuteration of i-PrOD-
d8 (Oppenauer oxidation) to produce D2, and the subsequent CH 
bond activation of the alkanes catalyzed by the catalyst mixture 
complex. This method was used to deuterate a wide variety of 
linear, branched, and cyclic alkanes at relatively moderate 
temperatures (120 °C) with deuterium contents from 14-39% (D-
cholestane) up to 92-97% (pentadecane). 
In another case, rhodium black was combined with the 
homogeneous Crabtree catalyst, [(COD)Ir(PCy3)(py)]PF6, 
resulting in improved deuterium incorporation into aromatic 
heterocycles and anilines compared to rhodium alone, delivering 
labeling levels of up to 95% (52-54; Scheme 22).[ 79 ] The 
reactions were performed under deuterium atmosphere at room 
temperature. Schou showed that the catalytic system was 
generally independent of the solvent used (THF, DCM, EtOAc). 
With other rhodium sources, such as Rh/C or Rh/alumina, the 
synergistic effect of the homo-/heterogeneous catalyst 
combination was limited and, thus, only minor differences were 
observed.  
 
Scheme 22. Combined homo- and heterogeneous catalysts in HIE.  
3.3 HIE reactions with nanoparticles 
The use of nanoparticles[80] can be described as existing on 
the borderline between homogeneous and heterogeneous 
catalysis. These nanoparticles are fully dispersed in an aqueous 
or organic matrix and invisible by human eye, however, they are 
still formally heterogeneous catalysts. Therefore, the critical 
reaction parameter continues to be the surface of the activated 
catalyst. Nevertheless, nanoparticles have shown very 
interesting reactivities and selectivities in a number of examples 
of HIE reactions. 
In an early example Sullivan et al. prepared Pd nanoparticles 
(with a mean diameter of 3.4 nm) through BH4 reduction of 
Na2PdCl4 in the presence of 4-dimethylaminopyridine (DMAP). 
[81]
 The particles were stable in solution for up to six months and 
were used for a selective H±D exchange at the 2,6-positions of 
pyridines in D2O. Oxidised Pd(II) complex species also present, 
as dissolved in the nanoparticle dispersion, played no part in the 
exchange. However, attempts to extend this activity and 
selectivity to other related molecules have shown that the 
presence of other functional groups (e.g. hydroxyl, amino) within 
the substrate of interest can have detrimental consequences for 
both the activity and the selectivity of the reaction. 
Pieters et al. reported an efficient H/D exchange method 
allowing the selective deuteration ĮWRWKHQLWURJHQDWRPSRVLWLRQ
in pyridines, quinolines, indoles, and alkyl amines with D2 in the 
presence of RuNP@PVP nanoparticles (55-57; Scheme 23). 
Enantiomeric purity was conserved in the labeled compounds, 
where labeling took place in the vicinity of the stereogenic 
center.[82] These results were further extended by applying the 
same Ru@PVP nanoparticles in the selective deuteration of 
amino acids and peptides (58-60; Scheme 24).[ 83 ] More 
specifically, an enantiospecific C±H activation reaction followed 
by deuterium incorporation at stereogenic centers was 
demonstrated. Mechanistic studies suggested that the selectivity 
IRUWKHĮ-position of the directing heteroatom results from a four 
membered dimetallacycle as the key intermediate. These results 
clearly demonstrate the potential of nanoparticles for the 
effective catalysis of C±H bond activation and pave the way for 
new enantiospecific C±H functionalization reactions. 
 
Scheme 23. Ru-nanoparticle-mediated HIE.  
 
 




In a further example, Ru/PVP nanoparticles were applied in 
the H/D exchange of phenyl rings in phenyl- or phenyl 
alkylphosphines, including diphosphines. This enables the 
comprehension of how different phosphorus ligands coordinate 
to the nanoparticle surface as analyzed by 31P-NMR 
techniques.[ 84 ] Recently, Jackson et al. have reported the 
application of electroactivated ruthenium particles, which are 
supported by an activated carbon cloth (Ru/ACC), that enables 
stereoretentive C±H activation at sp3 C±H sites bearing amine or 
alcohol groups.[85] 
Generally the applications of nanoparticles show different 
reactivity or selectivity compared to the already known 
homogeneous or heterogeneous HIE reaction systems. It is, 
therefore, anticipated that advances in material science will also 
enrich the armory of HIE reaction methods in the future.  
 
3.4 Conclusion  
 
Currently known techniques for heterogeneous labeling with 
deuterium/tritium atoms use the following representative 
combinations of catalyst and hydrogen isotope sources: Pd/C±
D2 or Pd/C±T2, Pd/C±(H2/D2)-D2O(DCl), Pd/C-Et3SiD-iPrOH-D8, 
Pd/C(en)-D2, Pd/PVP-D2, Pt/C±D2, PtO2±D2±D2O, Rh/C, or Rh 
black-D2, Ru/C±D2,  and, more rarely, cobalt or nickel metal. 
Generally, significant improvements have been made by 
applying the synergistic effect of catalyst mixtures to deliver 
higher deuterium contents. Nanoparticles have been identified 
as a new class of HIE catalyst, providing promise for further 
improvements in deuteration efficiency and selectivity.   
4. Homogeneous Catalysis 
As homogeneous catalysts are often single molecule 
species, their catalytic properties can be tuned by judicious 
manipulation of the ligands bound to the reactive metal centre. 
Furthermore, this mode of catalysis often leads to very mild, 
widely applicable and, indeed, industrially attractive reaction 
conditions. Therefore, parallel to advances in heterogeneous 
catalysis (vide supra), acid/base-mediated HIE, and even 
organocatalytic HIE methods (see section 2), homogeneous 
catalysis dominates modern research in HIE.[8a, 10a,c, 86, 87, 88,  89, 90, 
91, 92]
 Additionally, isotopic labeling remains in regular use for the 
measurement of KIEs[ 93 , 94 , 95 , 96 , 97 , 98 ] and metal-ligand 
cooperativity[ 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 ] in various 
applications of homogeneous transition metal catalysis. These 
latter mechanistic applications of homogeneous HIE fall outside 
the scope of the current organic synthesis focused discussion. 
4.1. Platinum 
In 1967, Garnett and Hodges reported one of the first 
examples of HIE employing homogeneous catalysts.[109] Using 
Pt(II) salts, in the presence of deuterated acetic acid, water, and 
hydrochloric acid, various arenes were labeled, albeit in a non-
regioselective manner (61ĺ62; Scheme 25, top). Many years 
later, Sanford and co-workers explored a similar deuterium 
labeling strategy using diimine-ligated Pt(II) catalysts, 63 
(Scheme 25, bottom).[110, 111, 112, 113] It was found that a bromo- 
rather than methyl-substituted ligand provided the most active 
catalyst, with this being hypothesized to originate from the 
greater propensity of the bromine to coordinate to and stabilize 
the metal centre. Related developments with Rh(I) bis-imine 
complexes have also been reported.[114] 
 
Scheme 25. Global aromatic HIE via homogeneous Pt(II) catalysis. 
The study of homogeneous palladium complexes in HIE 
processes has often been compared to analogous platinum 
FRPSOH[HV,QGHHGWKLVZDVWKHFDVHLQWKHHDUOLHURI6DQIRUG¶V
aforementioned deuterium labeling studies, where cationic 
bipyridine ligands were employed to produce advantageously 
Lewis acidic catalysts, 65 and 66 (versus 64), for the deuterium 
labeling of benzene in the presence of CD3CO2D (Scheme 
26).[110, 111, 112] Although both metals produced highly active HIE 
catalysts compared to the parent catalyst of the study (64), Pt 
was more useful than Pd, as Pt provided the most highly acidic 
catalyst.  
 




Homogeneous palladium catalysis has also been explored 
more fully in its own right for HIE processes. Recently, Yu and 
co-workers demonstrated that Pd(II)-catalysis can be effectively 
employed in ortho-directed HIE processes.[115] Using Pd(OAc)2 
under basic conditions in the presence of CD3CO2D, various 
weakly coordinating functionalities were able to affect ortho-
deuterium labeling in moderate to excellent yield (67ĺ68; 
Scheme 27). More weakly coordinating directing groups proved 
to be most reactive (for example, 69 versus 71). Furthermore, 
labeling via a six-membered metallocyclic intermediate (6-mmi) 
was found to be more efficient than the analogous 5-mmi (for 
example, 69 versus 72, Scheme 27). 
Skrydstrup and co-workers have developed a fundamentally 
different method for labeling organic molecules using Pd 
catalysis. With a two-chamber system, COgen, 73, was 
employed as a synthetically convenient CO source in the 
reductive carbonylation of aryl iodides (74ĺ75; Scheme 28).[116, 
117 ]
 In this manner, a range of isotopically-enriched aromatic 
aldehydes could be accessed without the necessity to label the 
aromatic C±H positions.  
 
Scheme 27. Pd-catalyzed o-directed HIE with aromatic compounds. 
 
Scheme 28. Dual 13C and D-labeling of aryl iodides. 
 
4.3 Ruthenium 
Since 2007, Ru-derived HIE methods have been developed 
on several fronts.[87] A number of methods have been developed 
to affect the deuterium labeling of molecules which lack strong 
coordinating functionalities. Among these, Leitner has reported 
the D-labeling of benzene derivatives (76ĺ77, for example) and 
heteroaromatic compounds using the Ru(II) pincer complex, 78, 
under relatively mild, albeit time-consuming, conditions (Scheme 
29, top).[118] A combined experimental and computational study 
revealed that site selectivity in labeling was largely based on 
steric effects. Mechanistically, after the loss of the dihydrogen 
ligand and agostic coordination of the unlabeled substrate (79, 
Scheme 29) the key step in the mechanism was reported to 
LQYROYHDı-bond metathesis between the substrate C±H and a 
hydride ligand on Ru(II) (79ĺ81 via 80). DFT-calculated 
energies showed that ortho-labeling was disfavoured both 
thermodynamically and kinetically (as shown versus meta-
labeling in the potential energy surface (PES); Scheme 29). 
 
Scheme 29. Sterically-selective labelLQJ RI WROXHQH XVLQJ /HLWQHU¶V 5X,,
pincer catalyst. 
In a related but less selective approach, Gorelsky and 
Nikonov reported the use of Ru(IV) trihydride precatalyst, 82, in 
the Ru(II)-catalyzed labeling of unactivated molecules, using 
C6D6 (Scheme 30).[119] In all cases, aryl and heteroaryl positions 
were labeled fastest (85, 86, and 89). In alkyl species, the extent 
of labeling varied markedly depending on the exact nature of the 
molecule, and required at least some weakly coordinating 
functionality to operate at all (for example, 90 versus 87 and 88). 
Potential reaction mechanisms were studied by DFT (Scheme 
31). Reductive loss of H2 rather than phosphine dissociation was 
found to be the most likely source of precatalyst initiation 
(82ĺ91). 
Periana and co-workers investigated Ru-catalyzed 
perdeuteration using a conceptually distinct approach.[120] Base-




Scheme 30. Ru-catalyzed HIE with aryl and alkyl groups using C6D6. 
 
Scheme 31. Proposed mechanism for Ru(II)-catalyzed HIE with 82. 
nucleophilic Ru(II) catalyst(s) in situ. The deuterium labeling of 
several water-soluble organic substrates showed that more 
electron-deficient molecules could be labeled most efficiently 
(93ĺ94; Scheme 32). It is also worth noting the slight 
preference for labeling adjacent to the (presumably) ortho-
directing carboxylate. 
Beller and co-workers were able to exploit the unusual and 
so-called Shvo catalyst,[ 121 ] 95 LQ WKH Įȕ-deuteration of 
biologically-relevant amine molecules (97ĺ98; Scheme 33).[122] 
On heating, the Shvo catalyst dimer breaks down into two 
distinct, catalytically active monomers: the dehydrogenated form 
96a, and the hydrogenated form, 96b. Together, they catalyze 
the reaction of 97 to 98 using various deuteratium sources 
(including IPA-d8 and D2O). This method was applied to a host 
of drug-type molecules, including 99 - 101. 
 
Scheme 32. Perdeuteration of organic molecules under nucleophilic Ru(II) 
catalysis. 
 
Scheme 33. Ru-FDWDO\]HGĮȕ-deuteration of biologically-relevant amines. 
The full significance of both monomeric forms of the Shvo 
catalyst becomes fully apparent in the reaction mechanism 
proposed by the authors (Scheme 34). Amine substrate, 102, 
first coordinates to the dehydrogenated catalyst monomer, 96a, 
producing the zwitterion, 103. In a ligand-assisted step, the 
amine is deprotonated, thus switching from a nitrogen- to 
carbon-centred coordination mode in 104. SubsequHQWȕ-hydride 
elimination produces enamine 105 and the hydrogenated form of 
the Shvo catalyst, 96b. In this form, isotope exchange with IPA-
d8 gives the deuterated catalyst, 96b-D. The aforementioned 
enamine, 105, undergoes migratory insertion with 96b-D to 
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deliver WKH ȕ-label in intermediate 106. Deprotonation of the 
cyclopentadienyl ligand by the metalled amine gives 107, 
LQVWDOOLQJ WKH Į-label in the final product amine, 108, and 
recycling 96a. 
 
Scheme 34. Proposed mechanism for Į,ȕ-deuteration of amines with the 
Shvo catalyst. 
 
Scheme 35. Ru-catalyzed Į-selective labeling of amines. 
In 2016, Gunanathan and coworkers published a ruthenium-
catalyzed Į-selective deuteration of amines, using D2O as the 
isotope source under basic consitions.[123] This method suitably 
FRPSOHPHQWV %HOOHU¶V Įȕ-selective method, proceeding via 
amine N±H activation and amide-ligated ruthenium deuteride 
intermediates (109ĺ110; Scheme 35). The mechanistic 
hypothesis was supported by isolation of mixed amine/amide 
complex, 112, from 111. 
At a similar time, Szymczak and Hale reported the selective 
DQG VWHUHRUHWHQWLYH GHXWHUDWLRQ RI Į-chiral amines (114ĺ115; 
Scheme 36).[124] This was achieved using judiciously selected 
electron-deficient Ru(II) catalysts (such as 113), bearing a 
rigidified ligand framework, promoting strong substrate binding 
and fast isotope exchange, thus, minimizing racemization via 
dissociation of planar imine intermediates. 
 
Scheme 36.  Regioselective and stereoretentive deuteration of Į-chiral 
amines. 
Beyond amines, ruthenium-derived catalysts have been 
explored for the regioselective labeling of aliphatic alcohols. 
Recently, Lin and Jia reported complementary precatalysts 116 
and 117, for the ȕ- DQG Įȕ-labeling of alcohols with D2O, 
respectively (Scheme 37).[ 125 ] Computations showed that 
precatalyst 117 produces hydrides that exchange with D2O more 
readily than for 116, leading to labeling of 118 DW WKHĮ-position 
to give 120 &RQYHUVHO\ ȕ-labeling to give 119 and 120 was 
facilitated by enolisation of aldehyde intermediates. 
Regioselective Ru-catalyzed HIE processes have also been 
exploited in the labeling of N-heteroaromatic substrates. In 2012, 
6FKQUFK DQG co-workers reported the regioselective 
deuteration of N-heterocycles using the Ru(0) cluster, Ru3(CO)12, 
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and tBuOD as the deuterium source (121ĺ123, via 122).[126] In 
some substrates, deuteration occurred at aromatic and benzylic 
positions accessible via nitrogen coordination, favouring the 
latter when both were available (molecules 124 and 125, 
Scheme 38). Conversely, indole-derived structures were 
deuterated at the electron-rich 3-position (126, Scheme 38). No 
in-depth mechanistic analysis was carried out by the authors. 
However, it was speculated that labeling of substrates like 124 
or 125 is likely to occur via a deuterated ruthenacycle, such as 
122. The mechanism for the labeling of indoles such as 126 
remains altogether unclear. 
  
 
Scheme 37. Complementary labeling strategies for aliphatic alcohols. 
 
Scheme 38. Ru-catalyzed directed HIE with N-heterocycles. 
Additional developments in ortho-directed HIE reactions 
using Ru catalysts have emerged in recent years. In the first of 
two key examples, Peris and co-workers showed that Ru(II) 
NHC complex, 127, could efficiently catalyze the ortho-directed 
deuteration of various N-heterocycles in the presence of MeOD 
(Scheme 39, top).[127] Similarly, Nolan and co-workers recently 
divulged the directed deuteration of a significantly broader range 
of coordinating functionalities using the Ru(IV) phosphine 
complex 128 and D2O as the key main isotope source (Scheme 
39, bottom).[128] 
 
Scheme 39. Directed o-HIE with various Ru(II) catalysts. 
Ru catalysis has also been applied to chemoselective HIE 
with alkenes. Grotjahn and co-workers applied bifunctional 
alkene zipper catalyst 129 to the isomerisation and deuterium 
labeling of various alkenes, producing selective vinyl and allyl 
labeling (130ĺ131, Scheme 40).[129] This process requires only 
very mild conditions and was purported to proceed via a series 




Scheme 40. Chemoselective labeling of olefins via isomerization using a 
bifunctional Ru(II) precatalyst. 
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In a complementary study, Lin and Jia reported the Ru(II)-
catalyzed labeling of vinyl functionalities of varying degrees of 
substitution using complex 132 (133ĺ134; Scheme 41).[130] The 
report includes impressive examples of labeling of homoaryl 
derivatives, as well as vinyl silanes and acrylates, but is, 
otherwise, limited in the presence of the one pyridyl example 
described. 
 
Scheme 41. Ru(II)-catalyzed deuterium labeling of vinyl groups. 
4.4 Rhodium 
The rich history of homogeneous Rh-catalyzed hydrogen 
isotope exchange[ 131 , 132 , 133 , 134 , 135 , 136 , 137 ] has continued to 
evolve over the last decade. The principles of directed HIE 
originally developed by Lockley, Hesk, and Jones[132, 133, 134, 135, 
136]
 have been applied by Li and co-workers using a bis-
phosphine, chelation-assisted Rh(III) catalyst series, led by 135, 
in the directed labeling of various N-heterocycles (136ĺ137; 
Scheme 42).[138] The catalyst structure was optimized by simple 
screening of available phosphine ligands. In general, more 
electron-donating phosphines provided more active catalysts, 
with 135 being optimal. Excessively large phosphines were less 
active and thought to hinder necessary coordination of substrate 
to Rh. Intriguingly, only those labeling sites most easily 
accessed via a metal-coordinating atom were found to have 
significantly increased D-incorporation with longer reaction times 
(138 and 139). Some base-sensitive sites were subject to 
decreased D-incorporation. This demonstrated an element of 
thermodynamic selectivity rarely encountered in HIE catalysis. 
7KHDONDOLQHQDWXUHDQGXOWLPDWHOLPLWDWLRQRI/L¶VFDWDO\VWVZDV
demonstrated in labeling acetophenone, 140, where only the 
acid-sensitive alkyl sites were exchanged. 
The RhCl3 catalyst was used as a precursor to an active 
species with complementary reactivity to that previously divulged 
by Lockley.[132, 133, 134] More specifically, the bis(3,5-
dimethylpyrazol-1-yl) acetate (bdmpza) ligand, 141, delivered an 
anionic Rh(III)-centred pre-catalyst, 142, that was able to 
deuterate both aryl and ȕ-alkyl positions of substrates bearing 
no strong directing group (143ĺ143a; Scheme 43).[139] Under 
identical conditions, the parent RhCl3.H2O was more selective 
for aryl deuteration (ĺb). A combined experimental and 
DFT investigation into the operative reaction mechanism 
using142 revealed that aryl labeling was kinetically favoured 
over alkyl labeling by 9.0 kcal/mol, via the shared catalyst 
resting state, 144. Additionally, C±H bond breaking was 
postulated to occur via a trifluoroacetate-assisted and redox 
neutral, concerted metalation-deprotonation (CMD) transition 
state 145 (Scheme 44).[139] 
 
Scheme 42. Directed HIE with N-heterocycles using basic chelation-assisted 
Rh(III) catalysts. 
 




Scheme 44. Rationale for aryl over alkyl labeling emplying Rh catalyst 142. 
Complementary to the work of Grotjahn (vide supra), 
Castarlenas and Oro reported a beautifully detailed method for 
WKH ȕ-selective deuteration of styrenes (147ĺ148) using N-
heterocyclic carbene (NHC) and 8-quinolinol-derived ligands 
within catalysts, such as 146 (Scheme 45).[140, 141] The reaction 
mechanism merits discussion, as detailed studies revealed the 
essential role played by all ligands bound to the Rh centre 
(Scheme 46).[141] From synthesised precatalyst, 146, exchange 
with MeOD gives the active catalyst, 146-d. Subsequently, the 
styrene, 149, can undergo migratory insertion across the Rh±D 
bond in one of two directions. Thermodynamic 1,2-insertion 
gives 150, but suffers from a high barrier to rotation towards 151, 
ultimately retarding the formation of Į-labeled product 152 via ȕ-
hydride elimination. Alternatively, kinetically-favoured 2,1-
insertion of 149 across 146-d gives intermediate 153 which, 
crucially, can freely rotate toward intermediate 154 to finally 
deliver the observed ȕ-labeled product 155. This analysis is 
further summarised by DFT-calculated energetics (Scheme 46, 
bottom).  
 
Scheme 45. Rh(III)-catalyzed ȕ-selective deuteration of styrenes. 
 
Scheme 46. Mechanistic analysis for Rh(III)-catalyzed ȕ-selective deuteration 
of styrenes. 
Labeling heteroatom X±H bonds can deliver valuable 
intermediates en route to labeling more complex organic 
molecules. Most notably, Carmona and co-workers have 
explored this concept for tandem silane 
deuteration/deuterosilylation protocols.[ 142 , 143 ] Employing an 
unusual cyclometallated phosphine complex, 156, silane 
labeling was achieved under extremely mild conditions for 
mono-, di-, and trisilanes using D2 or T2 as the isotope source 
(for example, see Et3SiHĺEt3SiD, Scheme 47).  
 
 




In an impressive application of this work, the deuterated 
silanes were later employed with the same catalyst as starting 
materials in the large-scale production of Į-deuterated silyl 
protected alcohols and amines (for example, 157). With 
observable solution-phase ligand fluxionality in 156, and its 
recovery unchanged after catalysis, D2 (or T2) gas was proposed 
to be activated by the ligand and metal together (156aЍ158). 
This example of metal-ligand cooperation to shuttle an isotopic 
label is complementary to that reported by Brookhart.[131] 
4.5 Iridium 
Among all transition metals employed in homogeneous HIE 
methods, iridium is arguably the most widely studied [86,  88, 90, 91, 
144, 145, 146]
. This is, in part, due to the vast and ever-expanding 
literature precedent in related hydrogenation reactions.[147, 148, 149] 
Despite interesting alternative Ir-catalyzed HIE methods (vide 
infra), such as for silanes,[150, 151] boranes,[152] alkenes,[153] and 
global aryl labeling,[ 139, 151, 154 , 155 , 156 , 157 ] there is a clear 
dominance of ortho-directed HIE in the published literature.[7, 10a,  
88, 90, 144, 146, 158 ]
 In this sub-field of Ir-catalyzed HIE, several 
catalysts (159 ± 162) were used extensively in the period up to 
2007, using D2 or T2 as the main isotope source (Scheme 48). 
Although  these catalysts remain in use,[159, 160, 161] focus has 
been placed on improved systems that have emerged within the 
past decade.  
Amongst these more recent studies, much emphasis has 
EHHQ SODFHG LQ LPSURYLQJ RQ WKH RULJLQDO GHVLJQ RI &UDEWUHH¶V
catalyst, 159, in labeling and alkene hydrogenation.[149] Despite 
its widely reported success, 159 is known to suffer from thermal 
deactivation via the formation of inactive, hydride-bridged, 
iridium clusters.[148] Similar effects have been documented for 
other iridium-based complexes.[162] 
 
Scheme 48. Popularised Ir(I) ortho-HIE precatalysts in use between 1995 and 
2007. 
In a notably singular crossover between &UDEWUHH¶VFDWDO\VW
and bis-phosphine catalysts, Hickey and co-workers 
developed163, a polymer-VXSSRUWHG YDULDQW RI +H\V¶ ELV-
phosphine catalyst, 161, which showed comparable ortho-HIE 
activity to 159 and 161, but with the practical benefit of simple 
catalyst filtration at the end of the reaction (Scheme 49).[146, 163]   
From 2001 ± 06, separate investigations by Nolan[ 164 ] and 
Buriak[165, 166] towards improved thermal stability and predictable 
chemoselectivity of Crabtree-like hydrogenation catalysts 
resulted in a series of electron-rich, NHC-ligated complexes 
(Scheme 50). Such species were first applied in ortho-HIE 
processes by Powell and co-workers.[ 167 ] In their study, 
complexes 159 and 164a ± 164c were employed under 
stoichiometric (classical µWULWLDWLRQ-OLNH¶FRQGLWLRQVZLWK WKHPRVW
active variant, 164cVKRZQWREHVXSHULRUWR&UDEWUHH¶VFDWDO\VW
(159) across the substrate range investigated. 
 
Scheme 49. Polymer-supported Ir catalyst in ortho-HIE. 
 
Scheme 50. The first NHC-ligated Ir hydrogenation catalysts explored in HIE. 
In extension, Kerr and co-workers studied the catalytic 
activity of complexes 164b ± 164f, showing most active complex, 
164e, to be highly active over an appreciable substrate scope (5 
mol% [Ir], 16 h, r.t.), and displaying a higher turnover frequency 
72) WKDQ +H\V¶ ELV-phosphine catalyst, 161.[168] Interestingly, 
the smaller complexes in the series studied by Kerr (164b and 
164c) were catalytically inactive in HIE (unlike the case reported 
above where these complexes were successfully employed in a 
stoichiometric fashion). Similar investigations by the same group 
later led to the discovery that small NHC/phosphine complexes 
such as 165a were also inactive as HIE catalysts, but larger 
variants 165d and 165e were active across a limited substrate 
scope.[169] 
The exploration of NHC-ligated Ir HIE catalysts had revealed 
promising (proof-of-concept) developments beyond the popular 
and established works of Hesk and Heys. Accordingly, Kerr and 
co-workers developed a synthesis of previously unattainable 
complexes 165f ± 165h, bearing large phosphine and NHC 
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ligands in the same ligand sphere (Scheme 51, top).[169, 170 ] 
These complexes have proven seminal within the ortho-HIE 
domain, and have among the highest activity,[144, 170] 
substrate/solvent scope,[159, 169, 170, 171 , 172 , 173 , 174 ] and tritiation 
reaction cleanliness[88, 175] of any such catalyst reported to date 
(see drug examples 166 -169, Scheme 51, bottom). 
 
Scheme 51. Highly-active NHC/phosphine Ir ortho-HIE catalysts. 
Additionally, ortho-HIE processes with these complexes 
have been studied experimentally and computationally,[170,   176] 
strengthening the case for an Ir(III)-based reaction mechanism, 
akin to that proposed by Heys.[91, 146, 177, 178] More specifically, 
kinetic isotope effect (KIE) measurements[170, 176] revealed that 
C±H bond cleavage was turnover-limiting in the reaction, and 
detailed NMR studies revealed the trans-geometry of the 
ancillary ligands.[170] The same study was also able to reveal the 
origins of the selective reactivity of such catalysts for 5- over 6- 
mmi substrates, citing dual kinetic and thermodynamic 
favourability for the 5-mmi (170 versus 171, Scheme 52). 
Ir(III)-catalyzed ortho-HIE has continued to flourish, with 
recent contributions from Salter,[146] Muri,[179] Kerr,[176, 180, 181, 182] 
Derdau and Atzrodt,[183,184] Tamm,[184] and others,[172] leading to 
improved applicability of a broader scope of drug-related 
molecules and ortho-directing functionalities (Scheme 53). 
Among recent advances, whilst developing a rare method for 
labeling primary sulfonamides, Kerr and coworkers considered 
directing group chemoselectivity in detail.[176] It was observed 
that the sulfonamide versus pyrazole selectivity in Celecoxib 
(172) and Mavacoxib (173) varied dramatically with catalyst 
choice (Scheme 54). Whereas encumbered NHC/phosphine 
catalysts, such as 165f, facilitated labeling adjacent to the 
pyrazole moiety, NHC/Cl catalysts, such as 174, facilitated 
selective sulfonamide labeling for the first time. Accompanying 
DFT studies revealed that the substrate binding event was likely 
to be product-determining, even though C±H activation 
remained rate-limiting (for example, see 175a versus 175b, 
Scheme 55).[176] Similar computational evidence was derived for 
 
Scheme 52. Calculated ı-CAM C±H activation step in Ir-catalyzed o-HIE. 
 
Scheme 53. Ir-catalyzed o-HIE with challenging substrates. 
 
 
Scheme 54. Catalyst-controlled site-selective labeling of sulfonamide drugs. 
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the formyl-selective labeling of aldehydes (Scheme 53, last 
example), where a smaller catalyst ligand sphere promoted 
formyl agostic C±H binding over the carbonyl oxygen.[185]  
Further in recent interesting developments, Derdau and 
Tamm divulged a series of P,N-bidentate ligated Ir(I) 
precatalysts, such as 176 and 177,  able to ortho-deuterate 
previously troublesome substrate classes such as N-Boc-
protected amines, sulfones, and encumbered sulfonamides 
(Scheme 56).[183, 184] 
 
Scheme 55. DFT-calculated rationale for directing group selectivity using 
catalyst 165f and sufonamide drug 172. 
 
Scheme 56. New Ir(I) precatalysts bearing bidentate ligands. 
Labeling organic molecules via homogeneous Ir-catalysis 
has also advanced beyond ortho- and formyl-selective HIE. 
Several non-directed C±H deuteration strategies similar to those 
described for other metals (vide supra) have been reported,[ 103, 
139, 154, 155, 156, 157, 186] but are not discussed here in detail. 
Chemoselective labeling of alkenes has also been explored 
using iridium. In 2008, Hartwig reported a method 
complementary to those of Grotjahn, and Castarlenas and Oro 
 
Scheme 57. Ir-catalyzed deuteration of alkenes. 
(vide infra), where pincer complex 178 was able to label vinyl C±
H positions with selectivity largely dependent on the specific 
steric environment of the substrate, albeit under air and moisture 
sensitive conditions (179ĺ180, Scheme 57).[153] Notably, this 
method was applied to a series of both simple and complex 
organic molecules (see 181 ± 184, Scheme 57). This method 
could be applied to global labeling of aromatic and 
heteroaromatic substrates. 
A more practical variant of this method was divulged by 
Nishimura and co-workers.[ 187 ] Using an in situ derived Ir(III) 
monohydride, 185, and D2O as the isotope source, an attractive 
range of mono-substituted alkenes could selectively deuterated 
at the vinyl or methylidene positions (186ĺ187; Scheme 58). 
Some of the most recent developments in isotopic labeling 
employing Ir catalysis have been applied to X±H moieties. 
Specifically, Nolan and Grubbs have independently reported on 
silane labeling.[150, 151]  Grubbs studied catalyst 188, while Nolan 
investigated 189a and 189b in Si±H and B±H labeling, 
respectively (Scheme 59).[152] 
 
4.6 Latest Developments 
As shown for ortho-HIE, selective functionalization within 
evermore complex molecules remains a worthy challenge in the 
broader realm of C±H activation. Furthermore, selective 
methods complementary to those already available are highly 
prized. A fine example of these goals was recently demonstrated 
by Chirik, Hesk, and co-workers,[ 188 ] who reported the Fe- 
catalyzed tritiation of pharmaceutical substrates under mild 
(albeit air/moisture-sensitive) conditions (190ĺ193, cf. Ir-
catalyzed 190ĺ192; Scheme 60). In addition to employment of 
a sustainable base metal, &KLULN¶V PHWKRG VKRZHG direct 
complementarity to ortho-HIE methods employing iridium, and 
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has been applied across a noteable range of drug-like 
substrates (Schemes 60 and 61). 
 
Scheme 58. Ir-catalyzed deuteration of alkenes with an in situ derived catalyst. 
 
Scheme 59. Heteroatom labeling employing homogeneous Ir catalysts.  
 
Scheme 60. Fe-catalyzed sterically-controlled HIE complementary to ortho-
HIE. 
 
Scheme 61. Examples of deuterium and tritium labeling from Chirik and Hesk. 
4.7 Conclusions 
 Homogeneous metal-catalyzed HIE dominates current 
efforts to achieve labeling in complex molecules by late-stage 
C±H functionalization.  Indeed, a broad range of directing groups 
and functionalities are now amenable to these selective labeling 
methods, and often by more than one class of catalyst or metal. 
Associated with this, the most attractive methods remain those 
where conditions are mild and most practicable, and where 
catalysts are readily handled within routine preparative reaction 
protocols. Accordingly, as researchers strive to establish more 
advanced methods, air and moisture stable techniques for broad 
adoption should be the target of future developments in the field. 
For directed labeling techniques, broadening the drug-like 
functionalities that can be used as directing groups should 








5. Conclusions & Outlook 
 
Owing to the broad significance of hydrogen isotopes, both 
historically and in modern chemical, biological, and ecological 
sciences, HIE method development remains highly relevant and 
vibrant. Associated with this, as a low-cost, easily handled 
radioisotope, tritium is spearheading modern radiochemistry and 
pharmacokinetic studies, adding further to the importance of HIE 
method development. 
The wide range of applications involving hydrogen 
isotopes makes their installation an important and continuing 
challenge to synthetic chemists. Despite the apparent simplicity 
of the transformation, hydrogen isotope exchange requires a 
continually evolving preparative toolbox in order to satisfy the 
escalating regio-, chemo-, and stereoselectivity demands set by 
practicing isotope chemists. Indeed, we have deliberately 
avoided any ranking of the synthetic methods described herein, 
since it is the increasing breadth of methods that is, and will 
remain, most important in tackling the incalculable variation in 
the necessary HIE approaches required within different drug 
design projects, as part of selective labeling of substrates for 
mechanistic studies, and beyond. It is envisaged that these 
requirements will continue to drive developments in 
homogeneous, heterogeneous, and acid/base-catalysis in order 
to expand on the existing methods available for isotope 
incorporation. The widespread use of embedded deuterium and 
tritium units makes efforts towards the further development of 
these fundamental synthetic transformations increasingly valued. 
Moreover, and of even more widespread resonance for 
preparative chemistry, the evolving synthetic developments in 
late-stage hydrogen isotope exchange provides increasing data 
resources with which to understand the fundamental nature of 
various C±H functionalization methodologies. For selective 
labeling protocols, a key synthetic challenge for future 
developments will be to further consider directing group 
chemoselectivity and innate regioselectivity in increasingly 
complex drug-like architectures. Additionally, further escalation 
of catalyst activity and selectivity is required in order to expand 
beyond the established array of sp2 functionalization methods 
towards the challenging goal of more widely successful sp3 
labeling. 
We hope that this review will provide a strong starting point 
for understanding the demands and applications within synthetic 
and biochemical processes across a wide range of disciplinary 
areas, and that the content will prove useful to chemists, 
biologists, and analytical scientists alike. 
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